Targeting HER2 in Prostate Cancer: Where to Next?-Reference-Cited by-同舟云学术

Targeting HER2 in Prostate Cancer: Where to Next?

Published:2007-01-20 Issue:3 Volume:25 Page:241-243
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Solit David B.¹,Rosen Neal¹

Affiliation:

1. Department of Medicine, the Human Oncology and Pathogenesis Program and Department of Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York, NY

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2006.08.8187

Reference40 articles.

1. Sliwkowski MX, Lofgren JA, Lewis GD, et al: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26:60,1999-70,

2. ERBB receptors and cancer: the complexity of targeted inhibitors

3. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

4. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

5. Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor α

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HER2 as a potential therapeutic target on quiescent prostate cancer cells;Translational Oncology;2023-05

2. Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics;Pharmacology & Therapeutics;2021-12

3. Semaphorin 3C as a Therapeutic Target in Prostate and Other Cancers;International Journal of Molecular Sciences;2019-02-12

4. Decline in arylsulfatase B expression increases EGFR expression by inhibiting the protein-tyrosine phosphatase SHP2 and activating JNK in prostate cells;Journal of Biological Chemistry;2018-07

5. Disruption of ETV6 leads to TWIST1-dependent progression and resistance to epidermal growth factor receptor tyrosine kinase inhibitors in prostate cancer;Molecular Cancer;2018-02-19